Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnosti ...

Group 1 - Insight Molecular Diagnostics Inc. (iMDx) announced participation in investor conferences hosted by H.C. Wainwright and Lake Street Capital Markets [1] - The H.C. Wainwright 27th Annual Global Investment Conference will take place on September 8-9, 2025, featuring a company presentation on September 8 at 5:00 pm ET [1] - The Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9) is scheduled for September 11, 2025, with a format of one-on-one meetings [1] Group 2 - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [2] - The company holds several trademarks, including GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ [2]

Core Insights - Oncocyte Corp. will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025, with CEO Josh Riggs and CFO Andrea James attending [1][3] - The focus of the discussion will be on Oncocyte's innovative diagnostic technologies and the progress towards commercializing a regulated organ transplant rejection monitoring test kit [2][4] Company Overview - Oncocyte is a diagnostics technology company that provides tests aimed at enhancing clarity and confidence for physicians and patients [4] - Key products include: - VitaGraft™: A clinical blood-based solid organ transplantation monitoring test - GraftAssure™: A research use only (RUO) blood-based solid organ transplantation monitoring test - DetermaIO™: A gene expression test for predicting response to immunotherapies - DetermaCNI™: A blood-based monitoring tool for assessing therapeutic efficacy in cancer patients [4][5]